NewsBenzingaRBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 Benzinga 2026.11.05 18:19 (GMT+0) Open on Benzinga Other news Reported Earlier: Oracle’s $165B New Mexico Data Center Project Faces Potential Delay As Power Developer Extends Air Permit Review Timeline - Bloomberg News Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100 Carlyle Group Targets $60 Billion Fundraising in 2026 as Inflows Rise Barclays Maintains Overweight on VF, Raises Price Target to $28 Reported Earlier: AmeriLife And Palantir Announce Enterprise Partnership To Bring AI-Driven Transformation To Insurance And Retirement Distribution Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32
Reported Earlier: Oracle’s $165B New Mexico Data Center Project Faces Potential Delay As Power Developer Extends Air Permit Review Timeline - Bloomberg News
Reported Earlier: AmeriLife And Palantir Announce Enterprise Partnership To Bring AI-Driven Transformation To Insurance And Retirement Distribution
